Adding rituximab to a lymphomes malins B (LMB) chemotherapy regimen increased three-year survival from 87% to 95% and raised event-free survival by over 10%, in pediatric patients with newly diagnosed advanced B-cell non-Hodgkin lymphoma (NHL), during a recently published phase 3 study.
The new regimen should be considered a “cure for the vast majority” of patients with B-cell NHL, “even those with the most advanced disease,” according to the investigators.
“These